摘要
目的探讨鼻渊软胶囊联合糠酸莫米松鼻喷剂治疗慢性鼻炎的疗效及对血清白细胞介素17(IL-17)、免疫球蛋白E(IgE)水平的影响。方法选取莱芜市钢铁集团有限公司医院2016年10月至2018年2月收治的慢性鼻炎患者98例,按治疗方法的不同分为研究组和对照组,各49例。两组患者均予以糠酸莫米松鼻喷剂治疗,研究组患者加用鼻渊软胶囊。两组均连续治疗4周。结果研究组总有效率为93. 88%,明显高于对照组的75. 51%(χ^2=34. 282,P <0. 01);与治疗前比较,两组患者治疗后鼻阻力,临床症状评分,以及IL-17和IgE水平均显著降低(P <0. 05),且研究组降幅更显著(P <0. 05);研究组患者不良反应发生率为6. 12%,明显低于对照组的18. 37%(χ^2=15. 882,P <0. 01)。结论鼻渊软胶囊联合糠酸莫米松鼻喷剂治疗慢性鼻炎疗效较好,可明显减轻炎性反应,且不增加不良反应。
Objective To investigate the clinical effect of Biyuan Soft Capsules combined with Mometasone Furoate Nasal Spray in the treatment of chronic rhinitis and its effect on the levels of serum interleukin-17( IL-17) and immunoglobulin E( IgE). Methods Totally 98 patients with chronic rhinitis admitted to Laiwu City Laigang Hospital from October 2016 to February 2018 were selected and divided into the study group and the control group according to different treatment methods,49 cases in each group. The patients in the two groups were treated with Mometasone Furoate Nasal Spray,on this basis,the patients in the study group were treated with Biyuan Soft Capsules. Both groups were treated continuously for 4 weeks. Results The total effective rate of the study group was 93. 88%,which was significantly higher than 75. 51% of the control group(χ^2 = 34. 282,P < 0. 001). Compared with before treatment,the nasal resistance,clinical symptom score,the levels of IL-17 and IgE in the two groups were significantly decreased after treatment( P <0. 05),and the decrease in the study group was more significant than that in the control group( P < 0. 05). The incidence of adverse reactions in the study group was 6. 12%,which was significantly lower than 18. 37% in the control group(χ^2 = 15. 882,P < 0. 01).Conclusion Biyuan Soft Capsules combined with Mometasone Furoate Nasal Spray are effective in the treatment of chronic rhinitis,which can reduce the inflammatory reaction without increasing the adverse reactions.
作者
李蕊
赵娟
LI Rui;ZHAO Juan(Laiwu City Laigang Hospital,Jinan,Shandong,China 271100;Shandong Shanxian Central Hospital,Heze,Shandong,China 274300)
出处
《中国药业》
CAS
2019年第12期71-73,共3页
China Pharmaceuticals
基金
山东省医药卫生科技发展计划项目[2015WS0567]
